Hematopoietic stem cell transplantation in acute promyelocytic leukemia, experience in Iran

Archives of Iranian Medicine

Volumn 14, Issue 5, 2011, Pages 332-334

  Alimoghaddam, Kamran ^a   Ghavamzadeh, Ardeshir ^a   Jahani, Mohammad ^a   Jalali, Arash ^a   Jorjani, Hoda ^a   Iravani, Massoud ^a   Hamidieh, Amir Ali ^a   Mousavi, Asadolah ^a   Bahar, Babak ^a   Behfar, Maryam ^a   Derakhshandeh, Roshanak ^a   Rostami, Shahrbanoo ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute promyelocytic leukemia; Allogeneic vs. autologous; Stem cell transplantation

Indexed keywords

ARSENIC TRIOXIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICINOL; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; DONOR; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRAN; NEUTROPHIL; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SIBLING; THROMBOCYTE;

ADOLESCENT; ADULT; BLOOD CELL COUNT; BONE MARROW EXAMINATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PATIENT SELECTION; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 80053040471     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002; 100: 4298-4302.
2. Sanz M, Grimwade D, Tallman M. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2009; 113: 1875-1891.
3. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; 29: 2753-2757.
4. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007; 20: 57-65.
5. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005; 23: 2396-2410.
6. Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 2009; 15: 1479-1484.
7. Sanz MA, Labopin M, Gorin NC, de la Rubia J, Arcese W, Meloni G, et al. Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2007; 39: 461-467.
8. Tallman M, Altman J. How I treat acute promyelocytic leukemia. Blood. 2009; 114: 5126-5135.
9. deBotton S, Fawaz A, Chevert S, Dombret H, Thomas X, Sanz M, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2005; 23: 120-126.
10. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood. 1998; 92: 1073-1090.